MD3368541T2 - Compoziții și procedee de inhibare a activității arginazei - Google Patents

Compoziții și procedee de inhibare a activității arginazei

Info

Publication number
MD3368541T2
MD3368541T2 MDE20180870T MDE20180870T MD3368541T2 MD 3368541 T2 MD3368541 T2 MD 3368541T2 MD E20180870 T MDE20180870 T MD E20180870T MD E20180870 T MDE20180870 T MD E20180870T MD 3368541 T2 MD3368541 T2 MD 3368541T2
Authority
MD
Moldova
Prior art keywords
methods
compositions
arginase activity
inhibiting arginase
compounds
Prior art date
Application number
MDE20180870T
Other languages
English (en)
Inventor
Eric B Sjogren
Jim Li
Zandt Michael Van
Darren Whitehouse
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of MD3368541T2 publication Critical patent/MD3368541T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Abstract

Invenţia se referă la o nouă clasă de compuşi, care prezintă activitate inhibitoare faţă de arginază şi la compoziţii farmaceutice care conţin compuşii invenţiei. De asemenea, în prezentul document sunt prezentate metode de tratare a cancerului cu inhibitori de arginaza, conform invenţiei.
MDE20180870T 2015-10-30 2016-10-28 Compoziții și procedee de inhibare a activității arginazei MD3368541T2 (ro)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562248632P 2015-10-30 2015-10-30
US201662281964P 2016-01-22 2016-01-22
US201662323034P 2016-04-15 2016-04-15
PCT/US2016/059342 WO2017075363A1 (en) 2015-10-30 2016-10-28 Compositions and methods for inhibiting arginase activity

Publications (1)

Publication Number Publication Date
MD3368541T2 true MD3368541T2 (ro) 2020-09-30

Family

ID=58631120

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20180870T MD3368541T2 (ro) 2015-10-30 2016-10-28 Compoziții și procedee de inhibare a activității arginazei

Country Status (35)

Country Link
US (4) US10065974B2 (ro)
EP (3) EP3693375B1 (ro)
JP (3) JP6833844B2 (ro)
KR (2) KR102434308B1 (ro)
CN (4) CN108271371B (ro)
AU (3) AU2016343656B2 (ro)
BR (3) BR122020022275B1 (ro)
CA (1) CA3003271A1 (ro)
CL (4) CL2018001134A1 (ro)
CO (1) CO2018004750A2 (ro)
CR (3) CR20210389A (ro)
CY (1) CY1123557T1 (ro)
DK (1) DK3368541T3 (ro)
EA (1) EA038276B1 (ro)
EC (1) ECSP18040250A (ro)
ES (2) ES2808988T3 (ro)
HK (1) HK1252560A1 (ro)
HR (1) HRP20201046T1 (ro)
HU (1) HUE054972T2 (ro)
IL (3) IL258731B (ro)
LT (1) LT3368541T (ro)
MA (2) MA43131B1 (ro)
MD (1) MD3368541T2 (ro)
MX (1) MX2018005294A (ro)
NZ (1) NZ742742A (ro)
PH (1) PH12018500899A1 (ro)
PL (1) PL3368541T3 (ro)
PT (1) PT3368541T (ro)
RS (1) RS60695B1 (ro)
SG (4) SG11201802961PA (ro)
SI (1) SI3368541T1 (ro)
TW (3) TWI734630B (ro)
UA (1) UA125289C2 (ro)
WO (1) WO2017075363A1 (ro)
ZA (4) ZA201803556B (ro)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX348422B (es) 2010-04-22 2017-06-12 Mars Inc Inhibidores de arginasa y sus aplicaciones terapeuticas.
SI2632927T1 (sl) 2010-10-26 2016-08-31 Mars, Incorporated Boronati kot inhibitorji arginaze
CR20210389A (es) 2015-10-30 2021-09-16 Calithera Biosciences Inc Composiciones y métodos para inhibir la actividad arginasa (divisional 2018-0282)
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
CN110352063A (zh) * 2016-11-08 2019-10-18 卡里塞拉生物科学股份公司 精氨酸酶抑制剂组合疗法
BR112019012589B1 (pt) * 2016-12-22 2022-11-29 Calithera Biosciences Inc Compostos e composição farmacêutica para uso no tratamento de câncer por meio da inibição de atividade de arginase e processo para a produção de composto
JP2020519583A (ja) 2017-05-12 2020-07-02 カリセラ バイオサイエンシズ，インコーポレイテッド （３ｒ，４ｓ）−３−アセトアミド−４−アリル−ｎ−（ｔｅｒｔ−ブチル）ピロリジン−３−カルボキサミドの製造方法
CN111491937A (zh) * 2017-12-22 2020-08-04 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的杂环化合物
SG11202007739XA (en) 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
US20210040127A1 (en) * 2018-03-13 2021-02-11 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
AU2019246728A1 (en) 2018-03-29 2020-08-27 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
EP3810615A4 (en) 2018-06-20 2022-03-30 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
US20220251116A1 (en) * 2019-02-06 2022-08-11 Guangdong Newopp Biopharmaceuticals Co., Ltd. Alkylboronic acids as arginase inhibitors
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
WO2021141751A1 (en) * 2020-01-07 2021-07-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
BR112023000047A2 (pt) 2020-07-02 2023-03-14 Incyte Corp Compostos de ureia tricíclicos como inibidores da v617f da jak2
WO2022016195A1 (en) * 2020-07-17 2022-01-20 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors
WO2023178285A1 (en) 2022-03-17 2023-09-21 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
JP3979783B2 (ja) 1997-07-29 2007-09-19 アルコン ラボラトリーズ インコーポレイテッド ガラクトマンナンポリマー及びホウ酸塩を含む眼科組成物
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
AU2001275870A1 (en) 2000-07-06 2002-01-21 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
CA2534484A1 (en) 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20090298912A1 (en) 2005-07-01 2009-12-03 The Johns Hopkins University Arginase II: A Target treatment of aging heart and heart failure
US20100189544A1 (en) 2007-07-12 2010-07-29 Sanyo Denki Co., Ltd. Counter-rotating axial-flow fan
JP5421272B2 (ja) * 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 眼病治療のための組成物及び方法
WO2009137378A2 (en) * 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
SI2389352T1 (sl) * 2009-01-26 2019-08-30 The Trustees Of The University Of Pennsylvania, Center For Technology Transfer Inhibitorji arginaze in postopki uporabe
MX348422B (es) * 2010-04-22 2017-06-12 Mars Inc Inhibidores de arginasa y sus aplicaciones terapeuticas.
SI2632927T1 (sl) * 2010-10-26 2016-08-31 Mars, Incorporated Boronati kot inhibitorji arginaze
EP2658580A4 (en) * 2010-12-31 2014-07-23 Corridor Pharmaceuticals Inc ARGINE STARTER AND USE METHOD
AU2012326109A1 (en) 2011-10-19 2014-05-29 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
ES2627347T3 (es) 2011-10-20 2017-07-27 Glaxosmithkline Llc Aza-heterociclos bicíclicos sustituidos y análogos como moduladores de sirtuina
MX355758B (es) * 2012-04-18 2018-04-27 Mars Inc Analogos constreñidos en el anillo como inhibidores de arginasa.
CA2890111A1 (en) * 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy
KR20160066554A (ko) * 2013-10-25 2016-06-10 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 ***的增效药物复合物及其制备方法
WO2016153078A1 (en) * 2015-03-20 2016-09-29 Opiyo Sammy Oyoo Use of suramin and arginase inhibitors in malignant neoplasia
MA42269A (fr) * 2015-06-23 2018-05-02 Calithera Biosciences Inc Compositions et procédés d'inhibition de l'activité de l'arginase
CR20210389A (es) 2015-10-30 2021-09-16 Calithera Biosciences Inc Composiciones y métodos para inhibir la actividad arginasa (divisional 2018-0282)
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne

Also Published As

Publication number Publication date
MA43131B1 (fr) 2020-07-29
KR102434308B1 (ko) 2022-08-19
US20170121352A1 (en) 2017-05-04
PT3368541T (pt) 2020-07-06
WO2017075363A1 (en) 2017-05-04
AU2020286278A1 (en) 2021-01-14
MX2018005294A (es) 2018-09-21
TWI775556B (zh) 2022-08-21
US20210061822A1 (en) 2021-03-04
CL2019000820A1 (es) 2019-08-09
AU2020286278B2 (en) 2022-03-17
BR112018008746A2 (pt) 2018-10-30
KR20180084063A (ko) 2018-07-24
IL288225A (en) 2022-01-01
UA125289C2 (uk) 2022-02-16
SG10201911402YA (en) 2020-02-27
CN113150015A (zh) 2021-07-23
DK3368541T3 (da) 2020-06-29
CL2018001134A1 (es) 2018-10-26
EP3368541B1 (en) 2020-05-27
JP2022071010A (ja) 2022-05-13
HUE054972T2 (hu) 2021-10-28
LT3368541T (lt) 2020-09-25
US10851118B2 (en) 2020-12-01
JP6833844B2 (ja) 2021-02-24
HK1252560A1 (zh) 2019-05-31
TWI710565B (zh) 2020-11-21
TW201726692A (zh) 2017-08-01
CN108271371A (zh) 2018-07-10
EP3368541A4 (en) 2019-07-17
ZA201803556B (en) 2021-02-24
IL281503B (en) 2022-01-01
SG11201802961PA (en) 2018-05-30
CL2019000819A1 (es) 2019-08-09
EP4011887A1 (en) 2022-06-15
TWI734630B (zh) 2021-07-21
PH12018500899A1 (en) 2018-10-29
JP7032583B2 (ja) 2022-03-08
JP2021075543A (ja) 2021-05-20
US10844080B2 (en) 2020-11-24
ES2910928T3 (es) 2022-05-17
CR20210389A (es) 2021-09-16
AU2016343656A1 (en) 2018-06-07
BR112018008746A8 (pt) 2019-02-26
HRP20201046T1 (hr) 2020-10-16
EA201891057A1 (ru) 2018-12-28
ZA201907091B (en) 2021-05-26
AU2016343656B2 (en) 2020-09-17
ES2808988T3 (es) 2021-03-02
CO2018004750A2 (es) 2018-10-31
US10065974B2 (en) 2018-09-04
IL258731B (en) 2021-04-29
RS60695B1 (sr) 2020-09-30
CY1123557T1 (el) 2022-03-24
MA50636A (fr) 2021-04-14
US20200223872A1 (en) 2020-07-16
EP3368541A1 (en) 2018-09-05
CA3003271A1 (en) 2017-05-04
NZ742742A (en) 2023-04-28
SG10202003966RA (en) 2020-06-29
AU2022203703A1 (en) 2022-06-16
BR112018008746B1 (pt) 2021-11-16
BR122020022275B1 (pt) 2022-05-03
CR20180282A (es) 2018-11-30
EP3693375B1 (en) 2022-02-16
KR20220118559A (ko) 2022-08-25
PL3368541T3 (pl) 2020-11-02
ECSP18040250A (es) 2018-10-31
ZA201907093B (en) 2021-03-31
CL2019000821A1 (es) 2019-08-09
SG10201911406TA (en) 2020-01-30
CN108271371B (zh) 2021-02-09
ZA201907092B (en) 2021-04-28
SI3368541T1 (sl) 2020-10-30
CR20210390A (es) 2021-10-19
CN113201002A (zh) 2021-08-03
JP2018533582A (ja) 2018-11-15
EA038276B1 (ru) 2021-08-04
BR122020022280B1 (pt) 2022-05-03
IL281503A (en) 2021-04-29
CN113150016A (zh) 2021-07-23
EP3693375A1 (en) 2020-08-12
TW202146028A (zh) 2021-12-16
IL258731A (en) 2018-06-28
US20180346489A1 (en) 2018-12-06
TW202110858A (zh) 2021-03-16

Similar Documents

Publication Publication Date Title
MD3368541T2 (ro) Compoziții și procedee de inhibare a activității arginazei
MD3559009T2 (ro) Compoziții și metode de inhibare a activității arginazei
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
PH12017501456A1 (en) Therapeutic cyclic compounds as immunomodulators
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
MD3371190T2 (ro) Compuși heterociclici ca inhibitori PI3K-gamma
EA201591509A1 (ru) Ингибиторы cdc7
PH12016501462A1 (en) Neprilysin inhibitors
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
PH12018502242A1 (en) Imidazolone compounds as human neutrophil elastase inhibitors
EA201501187A1 (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EA202191495A1 (ru) Композиции и способы ингибирования активности аргиназы
EA202191138A1 (ru) Композиции и способы для ингибирования активности аргиназы
GB2553684A8 (en) Ethynylxanthines, preparation and use for cancer treatment